Jenny Creed Geraghty - Clinical Genetic Scientist
Jenny Creed Geraghty is a clinical genetic scientist specialising in rare disease diagnostics. Her career trajectory (18+ years) has tracked across 3 continents, gaining experience at the bench, as team leader (LabPlus, Auckland District Health Board) and Regional Manager Sales & Marketing (Europe, Middle East & S. Africa) for cutting-edge genetic diagnostic companies such as Centogene, Blueprint Genetics and Invitae.
On the research front, she broadened her horizons as part of the clinical genetic research team at Weill Cornell Medical College in Qatar and also helped establish a proteomics research lab at the Royal College of Surgeons in Dublin.
Jenny believes that blockchain has sparked a revolution in the evolution of digital healthcare. Patients as CEO of their own healthcare team is the future vision, forged by converging frontier technologies including blockchain, DLT, AI and IoT. Our genome is our most intrinsic asset, inherited by rich and poor alike. Blockchain gives us the keys to truly own and securely exchange or monetise, this appreciating asset.
Hopefully Blockchain and federated AI can also be leveraged to break open silos of genomic data, allowing unprecedented exploration of the 98% “dark matter”of our genome, liberating new clues for health and personalised treatments for us all.